{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:51:53Z","timestamp":1760921513872,"version":"build-2065373602"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,19]]},"DOI":"10.7759\/cureus.94938","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:38:49Z","timestamp":1760917129000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcome and Safety of Combined Radiation Therapy and Maintenance Avelumab for Bladder Cancer: A Case Series"],"prefix":"10.7759","author":[{"given":"Daiki","family":"Ikarashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koyo","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanori","family":"Ariga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Obara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.12.002","article-title":"The financial burden of guideline-recommended cancer medications for metastatic urothelial carcinoma","volume":"10","author":"Contieri R","year":"2024","unstructured":"Contieri R, Martini A, Mertens LS, et al.. The financial burden of guideline-recommended cancer medications for metastatic urothelial carcinoma. Eur Urol Focus. 2024, 10:662-5. 10.1016\/j.euf.2023.12.002","journal-title":"Eur Urol Focus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10455.x","article-title":"Factors influencing post-recurrence survival in bladder cancer following radical cystectomy","volume":"109","author":"Mitra AP","year":"2012","unstructured":"Mitra AP, Quinn DI, Dorff TB, et al.. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012, 109:846-54. 10.1111\/j.1464-410X.2011.10455.x","journal-title":"BJU Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0176","article-title":"Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor","volume":"4","author":"Vandeveer AJ","year":"2016","unstructured":"Vandeveer AJ, Fallon JK, Tighe R, Sabzevari H, Schlom J, Greiner JW. Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor. Cancer Immunol Res. 2016, 4:452-62. 10.1158\/2326-6066.CIR-15-0176","journal-title":"Cancer Immunol Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles T","year":"2020","unstructured":"Powles T, Park SH, Voog E, et al.. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020, 383:1218-30. 10.1056\/NEJMoa2002788","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles T","year":"2023","unstructured":"Powles T, Park SH, Caserta C, et al.. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up. J Clin Oncol. 2023, 41:3486-92. 10.1200\/JCO.22.01792","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70082-8","article-title":"Systemic effects of local radiotherapy","volume":"10","author":"Formenti SC","year":"2009","unstructured":"Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009, 10:718-26. 10.1016\/S1470-2045(09)70082-8","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz LH","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, et al.. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016, 62:132-7. 10.1016\/j.ejca.2016.03.081","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi AB","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, et al.. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015, 16:e498-509. 10.1016\/S1470-2045(15)00007-8","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.08.009","article-title":"Prospective clinical investigation of the efficacy of combination radiation therapy with immune checkpoint inhibition","volume":"111","author":"Akama-Garren EH","year":"2021","unstructured":"Akama-Garren EH, Morris ZS, Sikora AG, Weichselbaum R, Schoenfeld JD. Prospective clinical investigation of the efficacy of combination radiation therapy with immune checkpoint inhibition. Int J Radiat Oncol Biol Phys. 2021, 111:1165-75. 10.1016\/j.ijrobp.2021.08.009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3445","article-title":"Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: a preliminary study","volume":"9","author":"Fukushima H","year":"2020","unstructured":"Fukushima H, Kijima T, Fukuda S, et al.. Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: a preliminary study. Cancer Med. 2020, 9:8355-63. 10.1002\/cam4.3445","journal-title":"Cancer Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow MA","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, et al.. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012, 366:925-31. 10.1056\/NEJMoa1112824","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa W","year":"2018","unstructured":"Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018, 18:313-22. 10.1038\/nrc.2018.6","journal-title":"Nat Rev Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","author":"Boyerinas B","year":"2015","unstructured":"Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015, 3:1148-57. 10.1158\/2326-6066.CIR-15-0059","journal-title":"Cancer Immunol Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2494995","article-title":"Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab","volume":"14","author":"Osborne N","year":"2025","unstructured":"Osborne N, Rupani A, Makarov V, Chan TA, Srivastava RM. Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab. Oncoimmunology. 2025, 14:2494995. 10.1080\/2162402X.2025.2494995","journal-title":"Oncoimmunology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00153","article-title":"Radiation as an immunological adjuvant: current evidence on dose and fractionation","volume":"2","author":"Demaria S","year":"2012","unstructured":"Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol. 2012, 2:153. 10.3389\/fonc.2012.00153","journal-title":"Front Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/425253-clinical-outcome-and-safety-of-combined-radiation-therapy-and-maintenance-avelumab-for-bladder-cancer-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:38:54Z","timestamp":1760917134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/425253-clinical-outcome-and-safety-of-combined-radiation-therapy-and-maintenance-avelumab-for-bladder-cancer-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,19]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.94938","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,19]]}}}